PTC Therapeutics and Eli Lilly to Acquire Sangamo Assets for Up to $264M in Bankruptcy Auction, Bolstering Rare Disease Pipelines

August 17, 2026

Endpoints News USA

Overview

PTC Therapeutics and Eli Lilly are set to acquire parts of the bankrupt gene editing biotech Sangamo for up to $264 million following an auction. PTC Therapeutics will acquire Sangamo’s Fabry disease candidate, isaralgagene civaparvovec (ST-920), for $111 million upfront plus potential milestone payments. This strategic acquisition by both companies aims to strengthen their respective rare disease gene therapy pipelines, accelerating the development of treatments for intractable conditions.

In Depth

Key Findings

PTC Therapeutics and Eli Lilly are poised to acquire segments of the bankrupt gene editing biotechnology company Sangamo, with the total transaction value potentially reaching up to $264 million through a bankruptcy auction. Specifically, PTC Therapeutics will obtain Sangamo’s Fabry disease candidate, isaralgagene civaparvovec (ST-920), for an upfront payment of $111 million, complemented by potential milestone payments.

Technical / Clinical Details

Isaralgagene civaparvovec (ST-920) is an investigational gene therapy designed for the treatment of Fabry disease. Fabry disease is a genetic disorder caused by a deficiency in the alpha-galactosidase A (alpha-Gal A) enzyme, leading to organ damage and severe symptoms. ST-920 aims to restore enzyme activity and slow or halt disease progression by delivering a functional alpha-Gal A gene to patient cells. This gene therapy employs an in vivo approach, utilizing an adeno-associated virus (AAV) vector to deliver the gene to target cells within the body. PTC Therapeutics’ acquisition of this pipeline asset signifies a strategic move to bolster its portfolio in rare diseases, particularly within the gene therapy sector.

Background & Context

Gene therapy has made significant strides in treating genetic disorders in recent years, though its development still entails high costs and risks. Sangamo was a pioneer in zinc finger nuclease (ZFN) gene editing technology but faced bankruptcy due to clinical development challenges and funding difficulties. Nevertheless, its promising pipeline assets remained attractive targets for other major pharmaceutical companies. This acquisition exemplifies a common trend in the pharmaceutical industry where companies seek to strengthen their pipelines and adapt to evolving competitive landscapes, reflecting a heightened interest in gene therapies, especially in the rare disease space.

Strategic Significance & Outlook

PTC Therapeutics’ acquisition of ST-920 has the potential to accelerate the development of an innovative therapy for Fabry disease patients. With a proven track record in developing and commercializing rare disease therapies, PTC is well-positioned to efficiently advance ST-920 within its integrated pipeline. Eli Lilly’s acquisition of other Sangamo assets is also expected to reinforce its gene therapy development in its respective areas of expertise. This M&A activity highlights a critical process within the biopharmaceutical industry: promising assets from struggling companies often become part of larger strategic portfolios, ultimately increasing the likelihood of delivering new treatments to patients. Future attention will focus on the clinical progress of ST-920 and how the acquired technology platforms will be applied to other disease treatments.

Source: https://endpoints.news/ptc-therapeutics-lilly-to-buy-up-bits-of-sangamo-in-bankruptcy-auction/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.